Good Clinical

In this weeks episode I sit down with A/Prof Rodger Tiedemann, a Consultant Haematologist, A/Prof of Medicine, Researcher, and advocate for medicines access and clinical trials in New Zealand.We begin by chatting about Rodgers involvement in multiple myeloma research and the treatment landscape, and how targeted therapies have improved survival rates for this type of cancer.We then centre the discussion on the challenges facing New Zealand's healthcare system, particularly in terms of access to modern medicines and clinical trials.New Zealand's funding for medicines is significantly lower compared to other countries with comparative GDPs, and we have a large 10 year deficit in access to new cancer treatments for Kiwi patients.For example, we rank 30th in GDP per capita from 218 countries. By this measure of national income, we fall between Germany and the UK, and ahead of France, Italy and Japan. However, while those countries each reimbursed 119-165 new medicines between 2016-2021, New Zealand reimbursed only 17... This lack of access also impacts clinical trial availability, as trials often require patients to have already received standard-of-care treatments, which may not even be funded yet in New Zealand. Consequently, pharmaceutical companies are less inclined to bring clinical trials to NZ, further limiting options for our patients. So what needs to be done to fix this? A significant frameshift in drug funding is critical for NZ. The valuation and budgeting of healthcare, increased funding for medicines, and the understanding of how this would benefit the NZ economy due to second- and third-order effects of new medicines (I.e., lower healthcare spending, faster time returning to work etc.). This would not only improve patient outcomes but also attract more clinical trials, which could also bring economic benefit.You can find out more about A/Prof Rodger Tiedemann here:https://www.linkedin.com/in/rodger-tiedemann-a2306580/  𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:- cancer treatment, blood cancers, multiple myeloma, immunotherapy, medicine access, New Zealand healthcare, clinical trials, haematology, cancer research

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this episode meet Professor John Windsor, a Consultant Surgeon, Professor of Surgery, and Director of the Surgical & Translational Research Centre at The University of Auckland. Our conversation focuses on the development of the Limpet drainage device at AperCure Surgical, a research-focused company aiming to commercialise radiological and surgical drain devices.The Limpet device has been designed to overcome the problems that stem from the discomfort and risks that patients face when standard percutaneous drains are used post-surgery. Typically, these drains, secured with stitches to prevent dislodgement, cause discomfort and pain, and if they come loose, it requires another procedure to reinsert them.The Limpet device aims to offer a more secure and comfortable alternative to traditional post-surgical drainage methods. We talk about how the device uses flexible materials that conform to the body, making it easier for patients to lie on and reducing discomfort during recovery.A key innovation is that the device also protects the drain's path, minimising the risk of snagging, kinking, or compression, which can lead to further complications. The product also focuses on making it easier to care for the wound site, thus reducing the risk of infections and improving the overall patient experience during recovery.You can find out more about Professor John Windsor here:https://www.linkedin.com/in/john-a-windsor-013b9725/Podcast Takeaways:Prof John Windsor has had an extensive career in medicine, surgical practice, academics, and Med Tech. His experience has driven him to focus on improving patient care, particularly addressing issues with surgical procedures and post-operative recovery. He discusses his transition into the field of medical innovation, where his interest in solving real-world clinical problems led to the development of medical devices aimed at improving patient outcomes.We talk about how certain unmet clinical needs, particularly in surgical drainage, prompted the development of the Limpet device. Surgeons noticed the discomfort and complications caused by traditional drainage methods, which led to research and innovation aimed at improving patient care. The Limpet device is undergoing trials in volunteers to ensure that it meets the standards required for later-phase trials and routine clinical use.We chat about the importance of collaboration between surgeons and engineers in the development of medical devices. Surgeons bring practical, real-world clinical knowledge, while engineers provide the technical expertise to design solutions that address the specific challenges faced by patients and healthcare providers.We also discuss the evolution of surgery from open procedures to minimally invasive techniques like laparoscopy. Laparoscopic surgery allows for smaller incisions, faster recovery times, and reduced risks of infection, marking a significant shift in surgical practices.Timestamps:00:00 Introduction02:49 The Journey from Surgery to Research06:10 The Evolution of Surgical Techniques08:54 Translational Research and Clinical Observations12:00 Innovative Approaches to Organ Failure14:50 Developing the AperCure Limpet Device26:33 Clinical Trials and Product Development31:35 Business Considerations in MedTech37:11 Future Directions and Advice for Innovatorsmedtech, surgical research, translational research, innovation, clinical trials, organ failure, bioengineering, medical devices, entrepreneurship, healthcare, surgery, surgical care

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series. In this latest episode meet Dr Patrick McHugh, a general practitioner located in Tairāwhiti, Gisborne.Patrick plays a role in several different organisations including Te Whatu Ora Tairāwhiti, Mātai Medical Research Institute, and the iwi health provider Turanga Health, where he's involved in a project exploring a heart-based mindfulness approach to assist individuals to manage their anxiety and improve their mental health.Our conversation focuses on heart rate variability (HRV), where studies have demonstrated that a low HRV is associated with aging and a decline in health. HRV measures the variability in the time between heartbeats, and higher variability is associated with better health and resilience, both physical and mental.HRV can be analysed to give an indication of activity in the sympathetic nervous system as a proxy marker for degrees of stress. Heart-based mindfulness practices, which involve techniques such as developing an observer state and using the heart as a centre of consciousness, aim to increase HRV and improve emotional regulation.Podcast Takeaways:Patrick's project with Turanga Health aims to assess the effectiveness and acceptability of a heart-based mindfulness intervention for adults with anxiety disorders in primary healthcare settings.HRV is a key measure of health, particularly mental health. Higher HRV is linked to better adaptability and emotional resilience, while low HRV is often associated with stress, anxiety, and poor mental well-being.The heart and mind are deeply interconnected, and heart-based mindfulness practices can help regulate emotional states by increasing HRV, leading to better mental and physical health outcomes.HRV can be used as a proxy to measure the balance between the sympathetic (stress) and parasympathetic (calm) nervous systems, providing insights into an individuals stress levels and emotional health. Timestamps:00:00 Introduction01:11 Dr. Patrick McHugh's Background and Roles01:43 Understanding Heart Rate Variability06:37 The Connection Between Heart and Brain08:47 The Importance of Mindfulness 10:28 Impact of Mental Health12:06 Research on Heart Rate Variability and Mindfulness15:02 Heart-Based Mindfulness Approach18:30 The Integration of Medicine and Mind-Body Connection21:52 Future Project Prospects & Group-Based Interventions28:43 The Importance of Human Interaction for Mental Health32:34 Future Research Directions and Projects

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.This weeks guest is Dr Jo Nunnerley, a physiotherapist and researcher based at the University of Otago. We chat about Jo's development of a virtual reality tool for supporting individuals with traumatic brain injury (TBI), a project supported by Te Titoki Mataora.Jo and her team have developed the tool alongside expert clinicians, physiotherapists, and individuals who have experienced TBI. The tool, set in a simulated café environment, helps patients practice navigating real-world social situations while identifying and managing fatigue and memorisation. Jo also talks about her personal experience of stroke, the commercialisation journey of the project, future plans to incorporate AI, and the importance of collecting biometric data to enhance the tool’s functionality.You can find out more about Dr Jo Nunnerley here:https://www.linkedin.com/in/jo-nunnerley/Podcast Takeaways:Traumatic brain injury affects up to 36,000 New Zealanders per year, ranging from a mild brain injury such as concussion, to more severe cases.Jo’s personal experience as a stroke survivor brought crucial insight into how fatigue can impact recovery and rehabilitation. The VR tool provides patients with a realistic, relatable environment for practicing social interactions and managing fatigue, which can be difficult to replicate in traditional clinical settings. Collaboration with individuals who have lived experience of TBI has been essential in creating a more effective and user-centred rehabilitation tool. The project is moving toward further development with plans to enhance the tool by incorporating AI, heart rate monitoring, and eye-tracking technology to better assess and support patient progress. The next steps include conducting larger clinical trials and introducing the tool into clinical care in New Zealand, with the potential to expand globally.Timestamps:00:00 Introduction to TBI05:50 Current TBI management regimes and inequities09:52 Jo's VR tool for TBI rehabilitation and how it works22:10 Jo's personal experience with stroke26:43 Developing the VR tool alongside TTM support32:10 Next steps for the VR project▶️ 𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:- Traumatic Brain Injury, Virtual Reality, Rehabilitation, Fatigue Management, Clinical Trials, HealthTech, New Zealand, Patient Care, Innovative Technology, Neurology

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this episode meet Dr Robyn Whittaker, the Director of Research Evidence and Clinical Trials at Te Whatu Ora, Health New Zealand.Our discussion focuses on Robyns involvement in Te Titoki Mataora and TTMs key role in fostering MedTech innovation in New Zealand. We talk about the challenges and opportunities of translating ideas into real-world medical solutions, with TTM providing essential support through funding, expert networks, and collaboration between clinicians, researchers, and industry partners.While New Zealand may not have the same financial resources as other countries, we discuss how a combination of resourcefulness, strong partnerships, and a focus on practical outcomes allows NZ to make significant impact in the MedTech space.Podcast Takeaways: Te Titoki Mataora plays a critical role in supporting MedTech innovation in New Zealand by providing funding, networks, and partnerships to help translate ideas into practical healthcare solutions.A key initiative is the clinical experience program, where postgraduate students shadow clinicians to identify real-world healthcare challenges and develop solutions, bridging the gap between research and clinical practice.The conversation highlights the importance of creating a supportive ecosystem that allows innovators to learn from failures and build future successes, even if their first ideas aren't viable.A challenge discussed is securing funding for the next stage of development, especially for scaling projects beyond New Zealand's small market and attracting international investment.Collaboration is Key! Partnerships between researchers, clinicians, industry, and government are crucial in maintaining New Zealand's momentum in MedTech innovation, despite limited resources compared to larger countries.Timestamps:00:00 Introduction and Overview03:57 Robyns Background08:50 The Realm of Clinical Trials in NZ12:45 Introduction to TTM and Robyns Involvement17:25 NZ's Position in MedTech25:43 Envisioning NZ's Future27:49 Challenges in The Current MedTech Ecosystem

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this episode I chat with two Senior Research Fellows within The University of Auckland, Dr Haruna Suzuki-Kerr from the Faculty of Medical & Health Sciences, and Dr Julie Choisne, from Auckland Bioengineering Institute.Dr Julie Choisne's research is in the realm of paediatric biomechanics, looking at how children grow, how their bones grow, and how muscle growth affects their movements and applying that knowledge to children that have bone deformities.Dr Haruna Suzuki-Kerr's research involves trying to develop a new technology that can help treat individuals with sensory neural hearing loss.The episode particularly focuses on the Future Leaders module and other associated modules under the health tech capability programme provided by Te Tītoki Mataora, which are a part of an initiative aimed at supporting emerging researchers, entrepreneurs, clinicians, and others alike into the MedTech fields. Julie and Haruna are both actively involved in the programme, and they share insights into the modules provided by Te Titoki Mataora and their experiences. We also discuss other topics such as the importance of MedTech and innovation in New Zealand and envisioning NZ's future in this space.Check out more about Te Titoki Mataora here: https://www.cmdt.org.nz/Podcast Takeaways:Early-career researchers face numerous challenges, including managing their first research projects, writing grants, and balancing personal and professional life. The health tech capability programme aims to support them through this transition.Beyond technical expertise, researchers need to develop soft skills, such as effective communication, networking, and collaboration, to advance their careers and succeed in grant writing and commercialisation.Learning from experienced professionals and forming networks with peers at similar career stages is crucial for growth and overcoming common challenges in the MedTech field.Researchers often focus too heavily on the technical side of their work and forget to highlight the broader impact. Programmes offered through Te Titoki Mataora help researchers clarify the long-term significance and user needs of their projects.New Zealand is becoming a hub for MedTech innovation, with successful biotech and health tech companies emerging. The Future Leaders module aims to foster this growth and help researchers contribute to this vibrant ecosystem.Timestamps:00:00 Introduction03:09 Insights on New Zealand's MedTech Ecosystem05:51 Challenges in Technology Development09:12 The Importance of Collaboration in Health Tech12:00 Overview of the Future Leaders Module14:50 Supporting Emerging Researchers18:10 Skills Development for Future Leaders20:53 Networking and Collaboration Opportunities24:03 Vision for the Future of MedTech in New Zealand𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:- MedTech, Future Leaders, New Zealand, Health Tech, Pediatric Care, Collaboration, Research, Innovation, Technology Development, Emerging Researchers

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series. In this episode, meet Dr Caz Hales, a registered nurse and academic working in the research field of obesity care within health systems, based at Victoria University of Wellington. Her research focuses on reshaping the approach to healthcare for people living with obesity by advocating for a shift from the stigmas surrounding obesity to creating equitible, safe, and accessible care environments.A key area of her recent research includes a new project venture with the help of Te Titoki Mataora, which involves the use of virtual reality (VR) technology as a training platform to create innovative educational tools for healthcare professionals, helping them better understand and care for people living with obesity.You can find out more about Dr Caz Hales here:Dr Caz Hales - LinkedInPodcast Takeaways:Caz emphasises the need to shift healthcare practices from removing the stigmatisation around obesity to creating environments that provide equitable, safe, and inclusive care for people living with obesity (PlwO).Caz’s research is rooted in collaboration with PlwO, their whānau/families, and communities to ensure that their voices and needs are at the centre of developing healthcare services.Caz is exploring innovative approaches, such as using a virtual reality (VR) education platform as a training tool to educate healthcare professionals on how to provide better care for PlwO, focusing on empathy, cultural safety, equipment use, and patient movement safety.Caz advocates for a human-centred approach to healthcare, ensuring that all patients, regardless of body size, have access to respectful, dignified care, including appropriate equipment and support.Timestamps:00:00 Introduction to Dr Caz Hales and her Nursing Background06:48 Pivoting into Academia07:53 Current Research Focusing on PlwO 11:05 Inequities in Healthcare Services for PlwO16:01 Importance of Use of Language and Frameworks22:06 Clinically Defining Obesity28:00 Downstream Impacts of a Lack of Equitable Environments for PlwO35:45 Caz's Project Supported by Te Titoki Mataora45:00 Future Directions in Research and Care 

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this episode, meet Dr Gavin Harris, Anatomical Pathologist from Canterbury Health Laboratories, who discusses the development of a diagnostic assessment tool using machine-learning algorithms to assess breast cancer aggressiveness and recurrence risk.We chat about several topics such as the process of training the algorithm on clinical data, the challenges of validation, and the regulatory steps required for commercialisation. He emphasises the importance of multidisciplinary collaboration, networks, and funding support from entities like Te Titoki Mataora, and shares his experience navigating the complexities of both the healthcare and commercial sectors. The ultimate goal is to provide a personalised tool that can improve clinical decision-making and patient outcomes by accurately assessing cancer recurrence risk and other components with over 95% accuracy.Podcast Takeaways:Gavin is developing an AI tool to improve breast cancer risk assessment by identifying tumours with aggressive biological signatures that might not be evident through traditional diagnostics, as well as the likelihood of tumour recurrence.His tool has the potential to identify genomic features of the tumour that would otherwise only be identified through expensive molecular testing that not everyone can currently access. Having such a novel tool available means increased access, lower cost, and reduced time required for diagnostics and assessment.The current accuracy of the tool is around 80%, but the team is aiming for a higher threshold preferably above 95%, to be confident in its diagnostic value.Gavin highlights the importance of multidisciplinary collaboration such as with specialists from oncology, pathology, and AI, as well as the support of entities like Te Titoki Mataora and Health New Zealand.The project has to meet several parameters related to FDA and TGA regulations, with a pathway to commercialisation taking 3-5 years, involving rigorous testing and validation on independent and international datasets.Gavin underscores how crucial research offices, innovation hubs, and funding bodies are in providing the necessary infrastructure and resources for such complex projects.Gavin reflects on how much he has learned in transitioning from clinical work to understanding the complexities of commercialisation, regulation, and scalability, emphasising the value of building strong networks and continuously learning.Timestamps:00:00 Introduction and Background03:07 Gavin Harris's Journey in Pathology05:53 Traditional Approaches to Breast Cancer Diagnosis11:00 Incorporating Algorithmic Approaches19:06 Funding and Project Support25:40 Research Collaborations30:00 Commercialisation and Regulatory Challenges41:15 The Support of Te Titoki Mataora47:35 Advice for Innovators in Healthcare _

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this latest episode, meet Prof. Maggie Huckabee, Founding Director and Chief Scientific Officer, and Emma Hayes, Chief Executive Officer, at Swaltech.Swaltech is a medical device company that have developed innovative assessment tools that clinicians can incorporate into treatment planning and rehabilitation for individuals with dysphagia. Swaltech have developed an app called BiSSkapp (Biofeedback in Strength and Skill Training) that works alongside a surface electromyography (sEMG) device to detect and display muscle activity using sensors under the chin. This allows dysphagia rehabilitation to be achieved in the individual's own home with remote clinician supervision.You can find out more about Swaltech here: https://swaltech.com/Episode Takeaways:Swaltech have developed an innovative, non-invasive solution for remote dysphagia rehabilitation, combining their BiSSkapp with a biofeedback device.Their solution works by placing electrodes under the chin, which connects to a tablet to provide muscle feedback, allowing for at-home use with clinician-prescribed settings.The adaptive biofeedback can adjust difficulty to patient progress, and personalised voice prompts from clinicians can be incorporated to help with progress and motivation.There are ongoing clinical trials at University of Canterbury and University of Florida. - Swaltech's aim is providing state-of-the-art dysphagia management, with future plans for paediatrics expansion and new product iterations.Chapters:00:00 Introduction to Dysphagia and Swaltech03:09 Understanding Dysphagia: Prevalence and Impact06:02 Clinical Interventions for Dysphagia08:55 Innovative Approaches to Swallowing Rehabilitation11:46 The Birth of Swaltech and Its Mission15:09 The BiSSkapp: Biofeedback in Strength and Skill Training18:05 Patient-Centric Design and Usability24:20 Commercialisation and Regulatory Strategy31:00 Future Aspirations for Swaltech 𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:- Dysphagia, Swaltech, MedTech, swallowing disorders, rehabilitation, biofeedback, clinical interventions, Parkinson's disease, stroke, paediatric dysphagia#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #healthcare #clinicaltrials #medicine #humanhealthanddiseases #medtech #dysphagia

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this episode, meet Dr. Yaara Yarmut, the Chief Regulatory Officer at Alimetry, a medical device company who have developed an innovative gastric monitoring device that performs body surface gastric mapping using an electrode array.Yaara discusses her journey from veterinary medicine to MedTech and how they differ, where Alimetry is currently at as a late-stage startup, and the regulatory challenges that may be faced by MedTech startups. Yaara also emphasises the importance of having a strong regulatory framework, the important role of advisory boards in supporting and fostering innovation, and the need for more funding and talent acquisition in New Zealand's MedTech industry scene.You can find out more about Alimetry here:https://www.alimetry.com/Podcast Takeaways:Yaara transitioned from veterinary medicine to MedTech due to a desire for innovation.Alimetry's gastric monitoring technology aims to simplify diagnosis for gastric disorders.Regulatory challenges can be significant for MedTech startups, especially in New Zealand.A strong regulatory framework is key and can enable innovation rather than hinder it.Advisory boards play a crucial role in guiding early-stage MedTech projects.Funding and talent acquisition are critical for the growth of the MedTech ecosystem.Learning from mistakes is essential in the MedTech industry.New Zealand's small market can pose challenges for MedTech companies seeking growth.Chapters:00:00 Introduction to MedTech Innovation03:04 From Veterinary Medicine to MedTech Leadership05:56 Alimetry's Gastric Monitoring Technology08:45 Navigating Regulatory Challenges in MedTech12:04 The Role of Advisory Boards in Innovation14:55 Building a Supportive Ecosystem for Startups18:10 The Importance of a Strong Regulatory Framework28:00 Yaara's Perspective on how to Invigorate NZ MedTech 𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:- MedTech, innovation, regulatory framework, startup ecosystem, gastric monitoring, advisory boards, funding, veterinary medicine, clinical trials, New Zealand #goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #healthcare #clinicaltrials #medicine #humanhealthanddiseases #gastricdisorders #medtech #Alimetry

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this episode, Dr. Grace Walker, Co-founder and Chief Regulatory Officer at Tautoko Technology discusses her work in developing a patch insulin pump with wraparound support and education software to improve diabetes management.One of Tautoko Technology's main goals is ensuring their device is accessible to all, so that it gets into the hands of those that need it most.You can find out more about Dr. Grace Walker and Tautoko Technology here: https://www.linkedin.com/in/gracewalkernz/Tautoko Technology - LinkedInDr Grace Walker - LinkedInPodcast Takeaways:Tautoko Tech is developing a patch insulin pump with support software to improve diabetes management.The company aims to make the device more accessible by offering the pump for free and charging for the consumables.Rural communities face challenges in accessing healthcare, and Tautoko Tech's solution aims to bridge the gap.The team is driven by the desire to make a difference and improve the lives of people with diabetes.Tautoko Techs plans to raise the funds required to bring their MVP to market.They are working on getting regulatory pre-submission ready and filing a patent for their next version, and then will proceed with hotel trials and clinical trials.Chapters:00:00 Introducing Grace Walker and Tautoko Technology01:05 The Problem Tautoko Tech is Solving03:50 Dr. Grace Walker's Journey and Passion06:58 The Impact of Diabetes on Rural Communities13:15 Making Diabetes Care More Accessible18:45 Discussing the Tautoko Tech Team20:17 Current Project and Future Plans22:08 Navigating the Regulatory Pathway 26:50 Considering Biocompatibility and User Experience29:03 Accuracy and Claims34:58 Plans for Pitching and Funding39:10 Advice to Aspiring Entrepreneurs

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this episode, Professor Grant Searchfield, Head of Audiology at The University of Auckland and Founder and Scientific Director of TrueSilence Therapeutics, discusses the development of a non-invasive polytherapeutic method for the treatment of Tinnitus. The method combines sound therapy, perceptual training, and psychological interventions alongside the support of machine learning to provide a personalised multifaceted approach to helping individuals with Tinnitus.You can find out more about Prof Searchfield and TrueSilence Therapeutics here: Professor Grant Searchfield - LinkedInTrue Silence TherapeuticsPodcast Takeaways:Tinnitus is a common complaint affecting millions of people worldwide.2. Current treatments for tinnitus have been limited in their effectiveness.3. Tinnitus is a network problem, involving multiple parts of the auditory system and brain.4. Personalised and tailored treatments are important for addressing individual differences in tinnitus.5. The use of biosensors and artificial intelligence shows promise in optimising treatment outcomes.Chapters:00:00 Introduction and Background03:12 Understanding Tinnitus as a Network Problem05:04 Exploring Treatment Approaches for Tinnitus09:43 The Importance of Personalized and Tailored Treatments for Tinnitus13:33 The Potential of Biosensors and Artificial Intelligence in Tinnitus Treatment𝐑𝐄𝐋𝐀𝐓𝐄𝐃 𝐊𝐄𝐘𝐖𝐎𝐑𝐃𝐒:tinnitus, treatment, non-invasive, auditory system, brain, sound therapy, perceptual training, psychological interventions, personalised treatment, biosensors, artificial intelligence#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #healthcare #clinicaltrials #medicine #humanhealthanddiseases Please share with your friends and family. Also don't forget to like, subscribe, and hit the notification bell to notify you if I post a new video. Much love and God bless

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this epsiode, Dr. Xuxu Amoozegar-Montero, founder of Uuna, discusses the problems with traditional bras and the innovative solution her company is developing. Uuna uses 3D scanning and knitting technology to create custom-fit bras that address issues of comfort, sizing inconsistency, and sustainability. The company is initially targeting the post-surgery market and plans to expand to a general market in the future.Dr. Amoozegar-Montero emphasizes the importance of understanding and working with the end user, networking, and perseverance in entrepreneurship.Podcast Takeaways: Traditional bras have numerous problems, including discomfort, inconsistent sizing, and unsustainable manufacturing.Uuna Studio uses 3D scanning and knitting technology to create custom-fit bras that address these issues.The company is initially targeting the post-surgery market and plans to expand to a general market in the future.Understanding and working with the end user, networking, and perseverance are key in entrepreneurship.Timestamps:00:00 Introduction03:00 Introducing Oona Studio06:00 The Inspiration for Custom-Fit Bras09:00 The Solution: 3D Scanning and Knitting12:00 Targeting the Post-Surgery Market14:30 The Role of KiwiNet and Te Tukimata Ora19:00 Expanding Skillset and Thinking Long-Term23:00 The Future of Oona Studio30:00 Advice for Entrepreneurs33:00 Where to Find More InformationKeywordsbras, 3D scanning, 3D knitting, custom-fit, sizing, comfort, sustainability, post-surgery market, general market, networking, perseverance

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.In this epsiode, Dr. Vickie Shim, a Senior Research Fellow at the Auckland Bioengineering Institute, discusses her work in neuromechanics and its application to injury and degenerative diseases, specifically mild traumatic brain injury (TBI). She explains that neuromechanics focuses on how brain tissue responds to external mechanical stimuli, such as impacts, and the potential damage that can occur.Dr. Shim's research involves studying the brains of high school rugby players throughout a season to track brain changes and correlate them with head impacts. The goal is to develop an AI-based tool that can predict recovery trajectories and inform personalized treatment plans for individuals with TBI.Podcast Takeaways: Neuromechanics focuses on how brain tissue responds to external mechanical stimuli, such as impacts.Mild traumatic brain injury (TBI) is a common form of TBI, with about 80% of all TBIs falling into the mild range.Repetitive head impacts, such as those experienced in contact sports or by combat soldiers, can lead to long-term brain degenerative changes and increased risk of neurodegenerative diseases.Dr. Shim's research involves studying the brains of high school rugby players to track brain changes over a season and correlate them with head impacts.The goal is to develop an AI-based tool that can predict recovery trajectories and inform personalized treatment plans for individuals with TBI.Timestamps:00:00 Introduction to Neuromechanics and Dr. Vickie Shim's Research01:22 Understanding Brain Tissue Response to Mechanical Impact06:22 The Prevalence and Impact of Mild Traumatic Brain Injury10:06 Tracking Brain Changes in High School Rugby Players19:04 Developing an AI-Based Tool for Predicting Recovery Trajectories 26:40 Personalized Treatment Plans for Mild Traumatic Brain Injury

Today’s guest is Dr Maddie White, Translational Scientist and Strategic Partnerships Manager at the Gillies McIndoe Research Institute in Wellington, New Zealand.This episode is brought to you by SAPRO Consulting.Dr. Maddie White, a translational scientist and strategic partnerships manager at Gillies-McIndoe Institute, discusses the role of translational scientists in moving research from the lab to real-world impact. She emphasizes the importance of translating academic ideas into commercially viable products or services.Dr. White shares her personal journey into translational science and highlights the need for more awareness and education about career opportunities in this field. She also discusses a specific project she is involved in, developing a topical cream for the treatment of vascular birthmarks in infants.Dr. White emphasizes the need for talent, infrastructure, and funding to drive the success of translational science in New Zealand.You can find out more about Dr White and The Gillies McIndoe Research Institute here:LinkedIn - Maddie WhiteWebsite - Gillies McIndoe Research InstitutePodcast Takeaways:Academic ideas need to be translated into commercially viable products or services to have a meaningful impact.A "translational scientist" is someone who takes scientific ideas from the lab and translates them into real-world products or services.Translational scientists play a crucial role in moving research from the lab to real-world impact.There is a need for more awareness and education about career opportunities in translational science.Talent, infrastructure, and funding are essential for the success of translational science. Partnerships between academia and industry are key in driving the translation of research into practical applications.Chapters00:00 Introduction to Translational Science01:00 Translating Academic Ideas into Real-World Impact08:04 Overcoming Stigma and Misconceptions13:18 The Importance of Money in Translational Science19:49 Creating Collaborative Networks for Impactful Research23:58 Developing a Topical Cream for Vascular Birthmarks26:21 Partnerships for Bringing Research to MarketKeywords:Translational science, research, lab, real-world impact, commercialization, academic, funding, talent, infrastructure, money, partnerships, topical cream, vascular birthmarks 

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series.Today’s guest is Dr Victor Dieriks, the Head of the Apha Synuclein Lab at the Centre for Brain Research at the University of Auckland. Dr Dieriks studies the role of alpha synuclein in the development of Parkinson's Disease and Multiple System Atrophy (MSA).Parkinson’s disease (PD) is currently the fastest-growing chronic neurological disorder globally. An estimated 12 million people are living with PD, with around 12,000 of those residing in New Zealand.Unfortunately, no treatments presently target the underlying mechanisms of PD, and clinical studies aimed at discovering disease-modifying medications are limited. This means that a truly effective, curative treatment remains years away. However, numerous interventions are available today that can significantly improve the quality of life for those with PD.Dr Victor Dieriks has two active projects with Te Titoki Matora, MedTech Research TranslatorProject #1: Developing a more New Zealand-centric approach to the management and treatment of Parkinson's disease. Dr Dieriks emphasizes the importance of actively involving patients and understanding their priorities, rather than solely relying on the perspectives of healthcare professionals and researchers.Patients1 with PD often express their desire for improved dignity and quality of life, rather than just a focus on a cure or restoring mobility.Project #2: involves the use of tears (eye fluid) as a potential biofluid source for detecting Parkinson's disease biomarkes. Tears are a relatively pure and stable biological fluid, making them a promising target for developing a non-invasive diagnostic test that can be easily obtained. A core aspect of this project is reducing the burden on the healthcare system, particularly the long wait times to see a neurologist for diagnosis. By developing a simple, tear-based test, patients can potentially bypass the need for more invasive procedures and receive earlier prognosis and treatment.Podcast Takeaways:Parkinson's disease is not a single disease, but rather a collection of diseases with multiple causesThe normal function of alpha-synuclein is not fully understood, but it is known to play a role in neuronal communication and potentially in the gut and microbiomeCurrent treatments for Parkinson's, like levodopa and deep brain stimulation, only address the symptoms and cannot stop the underlying disease progressionA major challenge is that current therapies are tested too late, only after 70% of the relevant neurons have already died.Early detection is key, and recent breakthroughs have shown that alpha-synuclein clumps can be detected in spinal fluid or even potentially in less invasive samples like skin or nasal swabs, years before symptom onsetWhile genetic risk factors can be screened for, they only account for a small percentage of Parkinson's cases. Other risk factors include environmental exposures like metals, pesticides, and viral/bacterial infections that cause inflammationIn the absence of a cure, lifestyle interventions like exercise, healthy eating, and moderate coffee consumption can help delay the onset and progression of Parkinson's. Exercise, in particular, has been shown to have neuroprotective effects mediated by the hormone irisin.The gut-brain axis is also implicated in Parkinson's, with constipation and other gut symptoms often preceding the motor symptoms.Chapters0:00 Introduction01:10 "Parkinson's Disease" is a misnomer02:50 Dieriks Lab Focus06:00 Peculiarities of Neurodegenerative Diseases09:00 Role of alpha synuclein14:00 Treatment's available for Parkinson's Disease19:00 Risk factors for Parkinson's Disease24:00 Alternative sampling methods for determining risk ofPD 27:20 Interventions for slowing development31:00 Coffee32:12 Gut-brain Axis35:25 New Zealand-centric approach to management and treatment of PD 39:00 Importance of having all stakeholders engaged44:30 Tears can predict risk of Parkinson's Disease?Keywords: Parkinson's Disease, TTM, Te Titoki Mataora, biomedical science, research, research translation, medtech, medical technologies, university research, intellectual property, commercialization.Early Detection of Parkinson's Diseases | Dr Victor Dieriks | TTM Ep02

Today’s guest is Dr Haruna Suzuki-Kerr, Research Fellow at the University of Auckland in the Auditory & Vestibular Translational Neuroscience Cluster.This episode is part of the Te Titoki Mataora Podcast Series, in collaboration with Te Titoki Mataora, the MedTech Research Translator.Hearing loss is a common problem, in fact 1 in 6 people experience some form of hearing loss. Broadly speaking, hearing loss can be broken down into conductive hearing loss - think glue ear or damage to the ear drum - or sensorineural hearing loss (SNHL). SNHL is the most common type of hearing loss, and is caused by a pathology of the cochlea, auditory nerve, or central nervous system.The problem - the inner ear apparatus is embedded deep within the skull, is very small, and thus is very difficult to study.Enter Dr Haruna Suzuki-Kerr. Haruna and her team, with seed funding fro m Te Titoki Mataori, are developing a novel, non-invasive, light-based, medical technology and device for the investigation of the 1) structure and 2) chemistry of the inner ear.To date Haruna and her team have assembled a multi-disciplinary team to inform the design of their medical device and increase the likelihood of commercial success. The initial proof of concept will be tested in sheep tissue, before moving into live sheep model, and then into man!Chapters00:00 Introduction and Background02:00 The Different Types of Hearing Loss04:50 Architecture of the Inner Ear07:00 Studying Sensorineural Hearing Loss11:00 Haruna's previous research experience and Holy Grail of this project14:30 Inception of the Idea and Design18:00 Why use light-based techniques?22:30 Current Status of the Project28:00 Commercialization Journey and TTM support36:00 Next Steps for the Project and the ultimate goalKeywords: hearing loss, sensorineural hearing loss, medical device, TTM, Te Titoki Mataora, biomedical science, research, research translation, medtech, medical technologies, university research, intellectual property, commercialization.Using Light to Elucidate the Secrets of the Inner Ear | Dr Haruna Suzuki-Kerr | TTM Ep02

Good Clinical has teamed up with Te Titoki Mataora, the MedTech Research Translator, to bring you the Te Titoki Mataora Podcast Series. Te Titoki Mataora (TTM) is a New Zealand-based organization focused on translating basic science into real outcomes in healthcare.Here to provide an background to Te Titoki Mataora, the current framework to support research translation and some forward thinking perspectives is Distinguished Professor Sir Peter Hunter. After identifying a need to translate basic science into real outcomes in healthcare Sir Peter Hunter and Di Siew founded the Consortium for Medical Device Technologies (CMDT). Over years this resulted in the spin out of a number of companies, as well as a bid for a MedTech Centre of Research Excellence (CoRE), and more recently Te Titoki Mataora, the MedTech Research Translator. Te Titoki Mataora aims to develop a New Zealand-wide approach to medical technology translation by collaborating with universities, Callaghan Innovation, and the healthcare system. Supported by the Ministry of Business Innovation and Employment (MBIE) and the University of Auckland, the organization provides funding and support through programs like the Research Acceleration Program (RAP) to help researchers and spin-out companies progress from ideation to commercialization. TTM has already funded 69 projects and aims to create more high-paying jobs and successful medtech companies in New Zealand.In Sir Peter's Words, "I don't see any reason why we can't be creating, over the next 10 years, another ten Fisher and Paykel Heathcares". KeywordsTe Titoki Mataora, TTM, Consortium for Medical Device Technologies, CMDT, medical technology, translation, New Zealand, research acceleration program, RAP, spin-out companies, funding, high-paying jobs, medtech ecosystemSound Bites"Te Taitoki Mataora is focused on translating basic science into real outcomes in healthcare.""TTM aims to create more high-paying jobs and successful medtech companies in New Zealand.""The Research Acceleration Program (RAP) provides funding and support for researchers and spin-out companies."Chapters00:00 Introduction and Background of Te Titoki Mataora (TTM)03:46 Collaboration for Medical Technology Translation09:06 The Research Acceleration Program (RAP)12:15 Future Aspirations for TTM

Today’s guest is Charlotte Bradshaw, the Founder & CEO of Evrima Technologies.This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/Evrima aims to solve the problem of finding patients for clinical trials by building networks of clinicians and integrating trial information into their workflow. The goal is to make it easier for healthcare providers to identify eligible patients and provide them with trial options, with the ultimate vision is to have a measurable impact on the clinical trial value chain, enabling research to happen faster and getting treatments to the people who need them.Evrima offers three products:evripath, a referral network that connects sites, CROs, and sponsors to pharmacists and GPsevrilink, a recruitment platform that securely delivers participant referrals to sites, andevriquest, innovating recruitment marketing solutionsIn this episode, Charlotte describes how the company was built based on feedback from clinical trial teams who struggled with outdated tools like spreadsheets, and emphasizes the importance of technology adoption and collaboration in the clinical trial industry.Charlotte also shares her experiences and challenges in starting and growing the business, including the decision to raise capital and the need for continuous learning and support.You can find out more about Charlotte Bradshaw and Evrima here: https://www.linkedin.com/in/charlottebradshaw/ https://www.linkedin.com/company/evrimatechnologies/posts/?feedView=all https://www.evrima.com/Podcast Takeaways:Raising awareness about clinical trials is crucial for the advancement of medicine and human health.Evrima aims to make it easier for healthcare providers to access trial information and provide it to their patients.Integrating clinical trial data into existing systems can help identify eligible patients and streamline the recruitment process.The ultimate goal is to have a measurable impact on the clinical trial value chain and ensure that treatments reach the people who need them.The clinical trial industry needs to adopt and embrace technology to overcome challenges and improve processes.Starting and growing a business requires making pivotal decisions, learning quickly, and seeking support from mentors and advisors.Entrepreneurs in the clinical trial space should prioritize mental health and self-care and build a strong network for guidance and support.Chapters00:00 Introduction and Background06:11 Identifying the Pain Points in Clinical Research09:31 The Traditional Approach to Finding Patients for Clinical Trials11:48 Integrating Clinical Trial Information into Healthcare Practice15:24 Measuring the Impact of Clinical Trial Solutions21:36 Raising Awareness and Reducing Taboos24:22 The Vision and Impact of Evrema29:01 Challenges and Decisions in Starting and Growing a Business32:13 Prioritizing Progress over Perfection36:30 Raising Capital and Building a Support Network43:30 Expanding the Reach of Evrima and the Future of Clinical Trials46:28 Lessons Learned and Advice for Budding EntrepreneursKeywords:clinical trials, awareness, patients, doctors, Evrema, barriers, participation, healthcare providers, integration, digital phenotype, impact, Evrima, EveryPath, EveryLink, referral network, recruitment platform, clinical trials, technology adoption, collaboration, starting a business, raising capital, challenges, continuous learning, supportSubscribe for free on Spotify - https://open.spotify.com/show/3Vet6Hn8XFMhprr2LrY3XS Get in touch in the comments below or head to: https://www.instagram.com/_good_clinical/Developing Technology to Streamline Clinical Trial Recruitment | Charlotte Bradshaw | Ep 26 

Today’s guest is John Robson (JR), General Manager at Bridgewest Ventures NZ, and Managing Director of BioOra, a company that is automating the manufacture of CAR T-cells.This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/The development of new technologies, whether it be medical or otherwise, requires a lot of resources. One of those resources is capital - financial capital. Financial capital for new ventures can come in many forms, including loans from Mom & Pop or the bank, angel investment, grants, or private capital.One of the forms of private capital is venture capital, or VC. VC is characterised by investment in young companies with growth potential. But it's not just about the money. As JR puts it, no founder has every said they were successful because they had an endless supply of money...In this episode, and I discuss:The idiosyncrasies of the New Zealand start-up ecosystemVenture Capital's role to play in the ecosystemBridgwest's portfolio of companies working in the CAR space....and much much more. You can find out more about John Robson and Bridgewest Ventures here: LinkedIn - John Robson (JR)LinkedIn - Bridgewest Ventureshttps://bridgewest.ventures/https://bioora.com/Timestamps:00:00 Teaser00:30 Introduction02:20 True Venture Capital vs. Vulture Capital05:00 Early Stage / Deep Tech Investment09:20 Improving the status quo - Infrastructure, Human Capital, Regulation16:00 Money follows success20:33 Shaping the world around you23:15 Doing more with less25:20 It's not just about the money26:10 Celebrating, and advertising, our successes29:45 Where does the money come from - Bridgewest edition34:30 Industry average is one in ten companies36:20 Early VC - TechTransfer Office involvement40:00 Founder Equity - Bespoke arrangements44:00 Bridgewest's CAR portfolio companies53:15 Advice for Biotech entrepreneursTo get in touch head to: https://www.instagram.com/_good_clinical/Vulture Capital vs. True Venture Capital | John Robson | Ep 25#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #venturecapital #vc #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #chatgcp #healthcare #clinicaltrials #medicine #humanhealth

Today’s guest is Cameron Quilter, and Clinical Research Associate (CRA) at Novotech.This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/In most Clinical Research Trials, there are three players:The "Sponsor" - the entity that is funding the research and could be a pharmaceutical company, insitute or other non-profit entity;The "Site" - hospital or private research clinical that is carrying out the research and administering the treatments and other procedures to the patients, andThe "Contract Research Organization", or CRO, which is delegated various responsibilities on behlaf of the sponsor.The Clinical Research Associate, or CRA, is the workhorse of the Sponsor or CRO. CRAs work with staff at the "site" to ensure that the research is conducted according to local and international regulatory and Ethical requirements, and helping to ensure that safety, rights and well-being of research participants are the priority.CRAs need to have keen attention to detail, a solid understanding of human biology and pharmaceutical science, and an ability to work well with all different personality types and manage the multitude of different "stakeholders". Oh, and being comfortable travelling to different cities every other day is a plus too!Despite this, the hardest part about a CRA role? Can often be getting a role in the first place! Yet once one has their foot in the door, the CRA role provides a spring-board to take your Science Career in a multitude of different directions.In this episode, Cameron and I discuss:How to get land a Clinical Research Associate (CRA) jobThe different careers paths that one can take after a CRA careerSome thoughts on the future of Clinical Research and biotechnology in New Zealand and AustraliaYou can find out more about Cameron and Novotech here:LinkedIn - Cameron QuilterLinkedIn - NovotechCameron Quilter | How to get a CRA job and how to make the most of it | Ep 24#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #chatgcp #healthcare #clinicaltrials #medicine #humanhealth

Today’s guest is Dr Zahra Champion, Executive Director of BiotechNZ.This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/Biotechnology is a broad category, and ranges from the use of yeast to brew beer, something humans have been doing for the past 9,000 years to manipulating our DNA to fight cancer, something we have been doing for last 20 years. Biotech is a platform technology that sits across all sectors - animal health, agriculture, human health etc.Modern Biotechnology has the potential to change lives and economies. New Zealand is at a crossroads, after years of onerous regulations stifling advancement in this area, the new government have made moves to re-vamp these regulations to unlock capacity.But to make a modern biotechnology industry happen, you don't just need benign regulations, you also need smart and motivated individuals and even smarter money. In this episode, Dr Champion and I discuss:What is Biotechnology and where the opportunities areWhat we can learn from other countries that have developed frameworks to support the implementation of biotechnologyAdvice for budding and future biotech entrepreneursYou can find out more about Dr Champion and BiotechNZ here:LinkedIn - Zahra ChampionBioTECH NZTimestamps:00:00 Teaser00:30 Introduction02:50 Regulatory framework holding Biotech back04:10 Negative implications of not having a Biotech industry05:30 What is Biotech08:50 Taking gene technologies from the lab to trial13:19 Medicinal cannabis: a case study14:00 New Zealand can adopt the gold-standard of regulations from the world15:15 Opportunity-cost of NOT having a thriving biotechnology industry18:20 Biotechnology is expensive21:00 Early-stage funding is available, but late-stage is not25:00 Developing a New Zealand flavour for biotech29:00 Australia vs. New Zealand31:15 Tall poppy syndrome & showing the world that we are open for business33:40 Short vs. Long-termism37:20 Aroa Biosurgery & Neuren Pharmaceuticals set an example38:50 Smart money = not repeating the same pitfalls40:30 Internal monologue or dialogue44:50 Advice for Biotech EntrepreneursDr Zahra Champion | The Future of Biotechnology in New Zealand Ep 23 | Ep23#goodclinical #goodclinicalpodcast #goodclinicalexplains #goodclinicalevents #goodclinicalnetwork #innovation #podcast #newzealand #commercialization #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #chatgcp #healthcare #clinicaltrials #goodclinical #goodclinicalnetwork #goodclinicalmedia 

Today’s guest is Dr Paul Hamilton, Clinical Director of Early Phase Research at Pacific Clinical Research Network (PCRN).This episode is brought to you by SAPRO Consulting: https://www.saproconsulting.com.au/New medicines are first studied in animals before they are tested in humans. Animal testing provides an insight into the efficacy, safety and tolerability of the new medicine. But before a new medicine can be tested on their intended patient population, the so-called "First In Human" (FIH) testing needs to take place. This is typically done in Normal Healthy Volunteers (NHVs) - i.e., a group of healthy individuals, not taking any prescription medications. Once the safety and tolerability of a new medicine has been substantiated in NHVs, only then can the medicine be tested in a patient.These types of trials are Phase 1 and 1b/2a trials, respectively, and are collectively called "Early Phase Trials". Early Phase trials are an exciting part of the clinical trials spectrum, as this is where the "Proof of Concept" is first determined. And, as Dr Paul Hamilton explains, can deliver impressive health improvements if the technology works as expected.As time progresses, new medicines become more targeted as we enter the era of "precision medicine". The drugs of tomorrow, are being tested today. The argument for participating in a clinical trial as a patient with a disease is compelling as Dr Hamilton explains in this podcast.In this episode, Dr Hamilton and I discuss:The importance of Early Phase Clinical TrialsWhy clinical trials need to be seen as a component of a patient's overall healthcare journey Future opportunities and challenges in the Clinical Research/Trials space in New ZealandYou can find out more about Dr Hamilton and Pacific Clinical Research Network (PCRN) here:Pacific Clinical Research NetworkPaul Hamilton - LinkedInPCRN - LinkedInTimestamps:00:00 Teaser00:22 Introduction01:30 Pivoting from from medicine and clinical research08:40 Paul's defining moment in clinical trials - Sofosbuvir12:30 Danicopan15:50 The future of medicine starts with Early Phase research21:30 Early Phase vs. Late Phase23:30 Setting up a new Early Phase research location29:25 Clinical trials have a responsibility for delivering healthcare33:00 Designing good early phase studies37:00 The Future of Clinical Trials in New Zealand44:25 Advice for getting into clinical researchDr Paul Hamilton | Clinical Trials are driving the Future of Medicine and Healthcare | Ep 22innovation #podcast #newzealand #commercialization #clinicalresearchassociate #technologytransfer #biotech #science #choices #country #entrepreneur #products #clinicalresearch #biotech #clinicalpractice #chatgcp #healthcare #clinicaltrials 

Today’s guest is Dr Brian Ward, Founder and CEO of Aroa Biosurgery, an ASX-listed, biotech company with with a ~$200 m AUD market capitalization.This episode is brought to you by SAPRO Consulting.Aroa Biosurgery is a New Zealand-based, ASX-listed biotech company that develops and commercializes novel products that promote wound healing and soft-tissue repair. Their proprietary products, developed from tissue taken from the fore-stomach of sheep, provide the body with structural and biological components that provide a head start in the healing process. Biotech is a hard business. It's expensive, time-consuming and the road to success is fraught with difficulty and complexity and many biotech companies never make it to profitability. Despite this, there are a number of biotech entrepreneurs with such a fire within them that the odds seem to be in their favour. Dr Ward's and the Aroa Biosurgery story is remarkable. From the idea, to the product, the manufacturing and commercialzation, the various challenges that have arisen have been overcome resulting in a compelling success story that would inspire any current, or aspiring, biotech entrepreneur. In this episode, Dr Ward and I discuss:1. The eureka moment that made Brian pivot from clinical practice to entrepreneurial endeavour2. The science and technology that underpins their novel products3. Brian's tips for aspiring biotech entrepreneurs - just get started, understand it will not be easy, be prepared for a "game of attrition" and surround your self with people smarter than you.You can find out more about Brian Ward and Aroabiosurgery here:LinkedIn - Dr Brian WardLinkedIn - Aroa BiosurgeryAroa Biosurgery Website

Today’s guest is Madhu Vyas, Theranostics Site Leader at Mercy Radiology, and Programme Lead at Unitec. This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/Nuclear Medicine, Molecular Imaging and Radiochemistry sound like terms pulled straight from a science fiction novel. Yet the use of radioactive materials for the purposes of diagnosing and treating disease - collectively referred to as theranostics (therapy + diagnostics) - are commonly place and an exciting field of discovery and development.But with so many different radioactive materials to choose from, each with their own characteristics, how do researchers and physicians choose the right one? And how is the radiation targeted to the desired organ or diseased tissue without damaging normal tissue?In this episode, Madhu and I discuss:1. The origins of nuclear medicine, molecular imaging and "theranostics"2. How radioactive material is targeted to different tissues within a patient for the purposes of either diagnosis or therapy3. What we can expect for the future of an area of medicine that is now hitting it's strideMadhu Vyas' passion for this field is palpable. When not working as the Theranostics Site Leader at Mercy Radiology, he is teaching the next generation of Medical Imaging technicians and also completing a PhD. Clearly, Madhu has discovered a way to wring more than 24 hours out of a single day!You can find out more about Madhu, Mercy Radiology & Unitec:https://www.linkedin.com/in/150880/https://www.linkedin.com/company/mercy-radiology/ https://radiology.co.nz/ https://www.linkedin.com/school/unitecnz/https://www.unitec.ac.nz/#newzealand #radiochemistry #radiation #radiationtherapy #theranostics #nuclear #nuclearimaging #molecularimaging #theranos #innovation #podcast #commercialization #science #entrepreneurship #innovation

Today’s guest is Will Charles, the Executive Director of Investment at UniServices.This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/UUniversities are a great place to get higher education, but they're also places where new ideas, concepts and technologies first take root. But how do new ideas make their way from the academic setting to the commercial setting?UniServices is wholly owned by the University of Auckland and is a not-for-profit, stand-alone company that provides support to researchers by helping them secure the funding and connections that can help them make a positive impact.Will Charles (great surname) has built an amazing career over time, tacking on new skills to make him a force in the world of commercialization of science and ensuring that University Intellectual Property simply doesn't gather dust on a shelf.In this episode, Will and I discuss:What Technology Transfer isHow UniServices supports acadmics and entrepreneurs alike3. Will's recommendations for budding entrepreneurs - top tip: Get in early, make mistakes in a low-risk environment (i.e., while at university).You can find out more about Will and UniServices here:https://www.linkedin.com/in/will-charles-b4005a5/ https://www.uniservices.co.nz/ https://www.linkedin.com/company/auckland-uniservices-limited/#newzealand #technologytransfer #innovation #podcast #commercialization #science #entrepreneurship #innovation

Today’s guest is Dr Rohit Katial, a Research Physician involved in Early Phase Clinical Trials in New Zealand.This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/Unfortunately, in New Zealand our access to modern medicines is well behind our OECD peers, and it typically takes 10 years before a new medicine is funded by Pharmac after being approved by Medsafe. Thus, Clinical Research is starting to do more and more of the heavy lifting to fill the gap between need and access. An interesting component of ClinicalResearch is Early Phase trials - which range from firstinhuman trials, to the initial studies in patients i.e., single ascending dose or multiple-ascending dose studies, aptly shortened to SAD or MAD trials. New Zealand is increasingly becoming an attractive place to conduct Early Phase research, by virtue of our diverse & young population, less onerous regulatory requirements and skilled workforce. Despite this, early phase ClinicalResearch is not an obvious career choice for those studying or participating in medicine. This is a challenge that will need to be addressed if we are to make the most of the opportunity that is before us.In this episode, Dr Rohit Katial and I discuss:1. His journey from mainstream medicine to early phase clinical research2. the core skillset that is needed to be proficient as an early phase clinical trials investigator3. Some of the exciting trials Rohit has been a part of....hint: gene editingYou can find out more about Rohit and New Zealand Clinical Research here: https://www.linkedin.com/in/rohit-katial/ https://www.linkedin.com/company/nzcr-christchurch/ https://www.nzcr.co.nz/#newzealand #clinicalresearch #innovation #podcast #clinicalresearchassociate #principalinvestigator #clinicaltrials #CRISPr #geneediting

Today’s guest is Shamubeel Eaqub, and economist, author and commentator. This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/In this episode Shamubeel and I discuss New Zealands productivity has not kept up with our OECD peers. Reasons for this include some things we cannot change, such as the fundamental realities of our small population and remote location at the bottom of the South Pacific, but also things we can, including policy settings, institutions, incentives, long-termism, and culture. Some very impressive companies have been built in New Zealand by some truly great minds, yet it would seem that the success of these companies has not been due to the settings, but rather in spite of them. https://open.spotify.com/episode/2zKFT444A8FhtpnWlJx2Ci?si=6d1621a6b10e41baYou can find out more about Shamubeel here:https://www.linkedin.com/in/eaqub/#newzealand #incentives #innovation #country #commercialization #government #economy #productivity #universities #biotech #risk #shorttermism #choices #geography

Today’s guest is Natalia Lopez, the Co-Founder and Chief Operations Officer of Kitea Health. This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/In our first episode of 2024, we are picking up where we left of in 2023 with another guest from Kitea Health - this time with Chief Operations Officer Natalia Lopez.We talk about Natalia's journey from the automotive industry to Medical technology, the importance of developing meaningful skills to bridge the gap between the science "bench-top" and the patient, and dive a little deeper into the technology that underpins Kitea's novel deveice of the monitoring of Physiological Pressure. This was a very inspiring discussion, and we're looking forward to the day where Kitea's vision for proactive healthcare is a reality.You can find out more about Natalia Lopez and Kitea Health here:https://www.linkedin.com/in/natalia-lopez-a34457147/https://www.linkedin.com/company/kitea-health/https://www.kiteahealth.com/#research #clinicalresearch #clinicalresearchassociate #healthcare #research #pharmaceuticals #podcast #podcasts #medicine #medicalresearch

This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/Today’s guest is Dr Simon Malpas, the Co-founder and CEO of Kitea Health. Simon is a distinguished New Zealand scientist and entrepreneur, and has co-founded three successful medical device & life science companies from his research, including Kitea Health, a Start up company transforming healthcare for people living with chronic conditions via the monitoring of physiological pressure.In this episode we discuss:How Kitea’s technology can help us graduate from a Reactive to a Proactive model of healthcare for chronic conditionsKitea’s plans to address the unmet clinical need in patients with hydrocephalusKitea’s commercialization journey to date, including their upcoming first in human clinical trial, slated for 2024.This was a super interesting discussion, with plenty of insights for budding life science entrepreneurs, and for someone with a passion for clinical research I will be watching their progress closely over the 2024.You can find out more about Simon Malpas and Kitea Health here: https://www.linkedin.com/in/simon-malpas-65052268/ https://www.linkedin.com/company/kitea-health/https://www.kiteahealth.com/research #clinicalresearch #clinicalresearchassociate #healthcare #research #pharmaceuticals #podcast #podcasts #medicine #medicalresearch Subscribe for free on Spotify - https://open.spotify.com/show/3Vet6Hn8XFMhprr2LrY3XSGet in touch in the comments below or head to: https://www.instagram.com/chat_gcppodcast/

This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/Dr Chris Wynne is the Chief Scientific Officer at New Zealand Clinical Research (NZCR). Chris has had a career of giant proportions in Clinical Research, and has been involved in a wide range of trials, including the early trials that laid the groundwork for the function cure of Hepatits C, down to the Pharmacokinetic studies for Juul - the infamous flagship vaping product of the late 2010s.In today’s episode you can expect to learn:What makes NZ a great place to do Clinical ResearchWhy the language of Clinical Research, and science more broadly, doesn’t translate well into marketingChris’s hopes for the future of Clinical Research in NZ and abroadMuch much more...Always great to speak with Captains of Industry, and Chris fits that description all too well. We need to capture the hearts and minds of more talented individuals to create products that will serve our populations in the future.You can find out more about Dr Wynne and NZCR Here:https://www.linkedin.com/in/chris-wynne-b0414241/https://www.linkedin.com/company/nzcr-christchurch/https://www.nzcr.co.nz/#research #clinicalresearch #clinicalresearchassociate #healthcare #research #pharmaceuticals #podcast #podcasts #medicine #medicalresearch

This episode is brought to you by SAPRO Consulting PTY Ltd https://www.saproconsulting.com.au/Courtney Rowse is the Clinical Operations Manager for MSD (ANZ). Clinical Research is one of those industries where most people get into it by accident. There are no consistent pathways into the industry, in fact if you were to sample 100 people, the only consistency would be inconsistency.Join us for Episode 11 where you can expect to learn:Why New Zealand is a great place to conduct Clinical ResearchWhy working at the site-level and Sponsor-level are not so differentThe "WHY" behind Courtney’s passion for the industry- and much, much more…I really enjoyed this conversation with Courtney, we may be biased, but we both agree that Clinical Research is a great industry to be a part of. Every now and then we need a good reminder that everything we do is centered on the patients we serve.You can find out more about Courtney and MSD here:https://www.linkedin.com/in/courtney-rowse-7592a21a7/https://www.linkedin.com/company/msd-australia/#research #clinicalresearch #clinicalresearchassociate #healthcare #research #pharmaceuticals #podcast #podcasts #medicine #medicalresearch

Kieran Jina is Partner at Pacific Channel, a Venture Capital firm focusing on start-up companies using breakthrough science and advanced engineering to seucure the future of Health, Environment and Food, aka "Deep Tech". Their second Fund "Pacific Channel Fund II" is the largest fund of its type and sector in New Zealand.Venture Capital has a certain mystique to it. What does a Venture Capitalist do, where do they get their money from and how to they choose the companies they invest in,....and importantly.... do you have to wear Patagonia?Join us in Episode 10 where Kieran and I discusswhy Venture Capital is pivotal for a functioning startup ecosystemthe similarities between capital raising for a VC fund, and the capital-raising that is done by startup founderswhat makes a good venture capitalisthow to get started in Venture Capital........and much much more.You can find out more about Kieran, Pacific Channel and Upstream here: https://www.linkedin.com/in/kieran-jina-63202752/https://www.linkedin.com/company/pacific-channel-limited/ https://www.linkedin.com/company/upstreammedicaltechnologiesltd/#venturecapital #investment #medtech #medical device #research #clinicaltrials #clinicalresearch #podcast #podcasts #medicine #healthcare #medicalresearch #venturecapital #startup #startups #entrepreneur #entrepreneurship

Dr Diana Siew is the Strategic Partnerships Lead for the Bioengineering Institute and the Co-Founder of the Consortium for Medical Device Technologies (CMDT).Twelve years ago, there was not much in the way high-value Medical Research commercialization - publicly-funded research was sitting idle, and international companies were bypassing New Zealand in favor of other countries. Dr Siew has been pivotal in growing New Zealand's capacity in Research Commercialization, particularly in the realm of Medical Technologies (MedTech).Join us in Episode 9 where Diana and I discuss why the CMDT was started, the importance of screening-out bad ideas early, how the ABI/CDMT achieve high rates of success, opportunities for the next 12 years....and much much more.You can find out more about Diana, the ABI and CMDT:https://www.linkedin.com/in/diana-siew-05139310/https://www.linkedin.com/company/auckland-bioengineering-institute/https://www.cmdt.org.nz/

Hanie Yee is the COO of Alimetry, a New Zealand-based MedTech company developing a device for the non-invasive diagnosis of gastric disorders; as well as the Investment Committee Chair for the Return on Science MedTech and Surgery Investment Committee.Hanie began her career in Clinical Research and worked with some of the big names in the industry including Genetech and Takeda, before moving to Fisher & Paykel, the most valuable company on New Zealand's stock exchange. After catching the entrepreneurship bug by way of an MBA, Hanie jumped aboard the start up company Alimetry, and has since contributed to what is one of New Zealand's most visible success stories in the MedTech sector. With her considerable experience, passion and expertise, Hanie is also fostering the next generation of MedTech entrepreneurs via her role as the Investment Committee Chair for the Return on Science MedTech and Surgery Committee.Join us in Episode 8 where Hanie and I discuss what inspired her to jump ship from the "Oil Tanker" that was her previous role to the "JetSki that is Alimetry, her philosophy when it comes to building a team to execute a vision, why New Zealand could become the Silicon Valley of MedTech world....and much much more.You can find out more about Hanie, Alimetry and Return on Science here: https://www.linkedin.com/in/haniey/https://www.linkedin.com/company/alimetry-ltd/https://www.alimetry.com/ https://www.returnonscience.co.nz/#medicine #surgery #surgeon #medical device #resarch #clinicaltrials #clinicalresearch #podcast #podcasts #medicine #healthcare #medicalresearch #venturecapital #startup #startups #entrepreneur #entrepreneurship

Julie Jones is the Founder and CEO of BioValeo, a New Zealand-based Contract Research Organization (CRO) providing services to companies developing Precision or Personalized Medicine Interventions.As medicine progresses, treatments are becoming more specific and tailored to the individual patient. Rather than bundling patients according to a high-level disease category, next generation treatments offer targeted interventions based on their specific disease characteristics - via their genetic or other biomarkers, for example. With this increased "Precision" or "Personalization", comes additional complexity, cost and regulatory scrutiny.oin us in Episode 7 where Julie and I discuss how Precision or Personalized Medicine trial differ from the "status quo" and why a bespoke CRO is needed to support these trials; the long-term healthcare and economic benefits of developing the supporting infrastructure for Precision/Personalized medicine trials; the exciting developments happening in this space in New Zealand....and much much more.You can find out more about Julie and BioValeo here:https://www.linkedin.com/in/julie-jones-64198215/https://www.linkedin.com/company/biovaleo-limited/https://www.biovaleo.com/#medicine #precisionmedicine #personalizedmedicine #research #clinicaltrials #clinicalresearch #podcast #podcasts #medicine #healthcare #medicalresearch #venturecapital #startup #startups #entrepreneur #entrepreneurship

Prof Greg O'Grady is a Professor of Surgery and the CEO of Alimetry, a New Zealand-based MedTech company developing a device for the non-invasive diagnosis of gastric disorders, such as neuromuscular dysfunction, Gut-brain disorder, Gastric Outlet Disease, to name a few.Greg's career is truly impressive, and with each rung he has climbed, the scale of the impact he can effect has increased. As a doctor & surgeon, he had the ability to improve the lives of one patient at a time. As a Researcher involved in the development of new techniques or procedures, he could improve the lives of more patients as those improvements were passed on to to other physicians & surgeons. As a Professor, he contributed to the education of the next generation of physicians, who would in turn improve the lives of their patients. But as the an Entrepreneur and CEO responsible for the development of a new medical technology that could improve the lives of as much as 10% of population, the scale of potential impact is unparalleled. It is the ultimate manifestation of the Hippocratic Oath of doing the most good, with the least harm.Join us in Episode 6 where Greg and I discuss what drove his career pivot from surgeon and surgical/medical research to commercialization, the scale of the problems that Alimetry's device is attempting to solve, why the Healthcare System has a so-called "immune-system" against the adoption of new technologies....and why this is a good thing...and much much more.You can find out more about Greg and Alimetry here:https://www.linkedin.com/in/greg-o-grady-b9520353/https://www.linkedin.com/company/alimetry-ltd/https://www.alimetry.com/#medicine #surgery #surgeon #medical device #research #clinicaltrials #clinicalresearch #podcast #podcasts #medicine #healthcare #medicalresearch #venturecapital #startup #startups #entrepreneur #entrepreneurship #hippocrates

Dr Ed Watson is the CEO of Aotearoa Clinical Trials, a network of hospital based clinical trial sites with over 20 years experience in clinical trials in Aotearoa - New Zealand.While it is well understood that Clinical Research plays a crucial role in advancing medical knowledge, and developing new therapies, we need to also recognize that it also contributes to the reduction of Health Inequities by providing access to next generation interventions before they hit the market.In an era where public health budgets are tightly constrained and the costs of modern technologies is ever-increasing, Clinical Trials need to be viewed as a vital component of the wider Healthcare System.Join us in Episode 5 where Ed and I discuss these topics and more. You can find out more about Ed and Aotearoa Clinical Trials here: https://www.linkedin.com/in/edwardwatsonnz/ https://www.aotearoatrials.nz/ https://www.linkedin.com/company/aotearoa-clinical-trials/#medicine #pharmaceuticals #resarch #clinicaltrials #clinicalresearch ##podcast #podcasts #medicine #healthcare #biotech #biotechnology #medicalresearch

Kris Vette is the Founder and CEO of Genecrypt, a platofmr providing end-to-end encryption of genomic data.As technology advances, we can expect genetic data to be used more frequently in both research and clinical settings. The promise of Precision medicine is we could use our unique genetic fingerprints inform healthcare decisions, and thus get the most out of our health, whether it be treatment, prevention or longevity.As more people have their DNA sequenced, it is critical that this information is kept secure. We are all aware of the importance of protecting our personal information - you wouldn’t share your home address or bank account details with the public for example. By virtue of its unique fingerprint, genetic data is the pinnacle of personal information - it is unique to that individual, and it is also enduring - i.e. it doesn’t change.Join us in Episode 4 where Kris and and I discuss the importance of genetic data in the future of medicine, how genetic data could be used, by both benevolent and malevolent parties, the value of having vast genetic "data lakes" that are accessible by multiple research entities, and some of the challenges that need to be overcome by founders developing medical technologies for the future.You can find out more about Kris here:https://www.linkedin.com/in/kris-vette-b8416620/https://genecrypt.io/#medicine #pharmaceuticals #resarch #pharma #neuroscience #podcast #podcasts #neurodegenerative #healthcare #biotech #biotechnology #medicalresearch #genomics #genetics

Dr Malvindar Singh-Bains' is a Research Fellow at the University of Auckland Centre for Brain Research, and her work is contributing to a paradigm shift in the way we investigate Neurodegenerative disease and design future treatments.One of Malvindar's areas of research is Huntington's Disease (HD), a neurodegenerative disease characterized by the accumulation of a mutated version of the aptly-named protein, Huntingtin. Traditionally, the accumulation of Huntingtin has been thought of as the molecular mechanism by which Huntington manifests. New evidence suggests that this is only the tip of the iceberg.Join us in Episode 2 where Malvindar and I discuss why Huntington's Disease is a model disorder for other neurodegenerative diseases; why there are many different types of mutant Huntingtin protein, ' and why science is yet to identify the "bad guy" variant or variants; and why Malvindar is confident that we will have a breakthrough in treatment of HD in our lifetimes. You can find out more about Malvindar and here research here:https://www.linkedin.com/in/malvindar-singh-bains-49801a226/ https://www.auckland.ac.nz/en/fmhs/research/cbr.html https://www.hdyo.co.nz/

Dr Sarah Diermeier is a pioneer in the world of RNA therapeutics.Armed with a PhD, she completed a post-doctoral research fellowship at the prestigious Cold Spring Harbour Laboratory in Long Island New York, before re-locating to New Zealand with her family to take up a tenured role at Otago University and founding Amaroq Therapeutics.Amaroq is a Venture-backed, pre-clinical, biotech start-up leveraging recent findings in long non-coding RNA to develop next generation RNA therapeutics in oncology.Join us in Episode 2 where Sarah and I discuss why our "junk" DNA may not be junk after all, what lncRNA is and why it took 60 years to discover, and what her company Amaroq is doing to leverage recent findings in the field lncRNA to develop novel drugs for treatment of various cancers.You can find out more about Sarah and Amaroq here:https://www.linkedin.com/in/sdiermeier/https://www.linkedin.com/company/amaroqtx/https://amaroqtx.com/about/https://twitter.com/oncogenie

Abbas Al-Murrani is a Health Economist and the Managing Director of Health Economist Consulting NZ.In this episode of Chat_GCP we explore why upfront costs are not the be all and end all, the importance of values in decision-making, and hear Abbas' take on why we need more Health Economists in New Zealand. You can find Abbas here:https://www.linkedin.com/in/abbasalmurrani/http://www.hec.nz/